查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
干癣：KOL 见解
年间契约型资讯服务
商品编码
1549555

干癣：KOL 见解

Psoriasis - KOL Insight
出版日期: 年间契约型资讯服务 | 出版商: FirstWord Group | 英文

价格
简介目录

牛皮癣最有效的治疗方法是什么？目前的治疗方法与研发的治疗方法在疗效、安全性和成本效益方面如何？ 据知名 KOL 表示，Bimzelx（bimekizumab）因其高效且副作用可控而成为处方最多的抗 IL17 药物。 Skyrizi（risankizumab）是抗 IL23 类别的领导者，Tremfya（guselkumab）也因其成本效益而受到欢迎。强生公司的口服药物 JNJ 77242113 显示出与 Otezla（apremilast）和 Sotyktu（deucravacitinib）等现有治疗药物竞争的巨大潜力。本报告透过专家意见和详细分析讨论了当前和未来的干癣治疗范例。

本报告调查的主要品牌

  • Humira
  • Enbrel
  • Remicade
  • Cimzia
  • Cosentyx
  • Taltz
  • Siliq/Kyntheum
  • Stelara
  • Tremfya
  • Ilumya/Ilumetri
  • Skyrizi
  • Otezla
  • Bimzelx
  • Sotyktu
  • piclidenoson
  • zasocitinib
  • JNJ 77242113

本报告回答的主要问题

  • 目前的干癣治疗方法在疗效、耐受性和易于给药方面如何使用和评估？与管道中的选项相比如何？
  • 哪些药物类别（抗 TNF 药物、抗 IL-12/23 药物、抗 IL-23 药物、抗 IL-17 药物、口服药物）最有可能影响处方趋势？
  • 生物相似药的推出以及目前批准的、新批准的和研发的药物的使用将在患者人口统计、治疗系列和适口性方面影响干癣治疗模式，是否会产生类似的影响？
  • 是否有任何有前途的管道产品？
  • 哪些临床试验可能会影响处方趋势，其结果将如何影响未来的干癣治疗？
  • 未来干癣的治疗状况将如何依患者细分和治疗状况变化？
  • KOL 对牛皮癣市场的需求和期望是什么？

目录

执行摘要

研究目的

抗TNF药物

  • Humira (adalimumab; AbbVie), Remicade (infliximab; Merck & Co./Johnson & Johnson Innovative Medicine), Enbrel (etanercept; Amgen), Cimzia (certolizumab; UCB)

抗IL17药物

  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
  • Siliq (US)/Kyntheum (EU)brodalumab; Ortho Dermatologics/LEO Pharma)
  • Bimzelx (bimekizumab; UCB)

抗IL12/23药物

  • Stelara (ustekinumab; Johnson & Johnson Innovative Medicine)

抗IL23药物

  • Tremfya (guselkumab; Johnson & Johnson Innovative Medicine)
  • Ilumya/Ilumetri (tildrakizumab; Sun Pharma/Almirall)
  • Skyrizi (risankizumab; AbbVie)

PDE IV 拮抗剂

  • Otezla (apremilast; Amgen)

酪胺酸激酶 2 抑制剂

  • Sotyktu (deucravacitinib; Bristol Myers Squibb)

在研药物

  • Piclidenoson (Can-Fite BioPharma)
  • Zasocitinib (TAK 279; Takeda)
  • JNJ 77242113 (Johnson & Johnson Innovative Medicine)

干癣治疗的未来前景和治疗趋势

  • 主要见解摘要
    • Risankizumab、guselkumab 和 bimekizumab 在干癣治疗范式中与其他药物具有很强的竞争性；生物仿製药允许生物製剂进行早期干预。

附录

KOL突发新闻

简介目录

What are the most effective treatments for psoriasis? How do current and pipeline therapies compare in terms of efficacy, safety, and cost-effectiveness? Leading KOLs evaluate Bimzelx (bimekizumab) as the most prescribed anti-IL17 due to its high efficacy and manageable side effects. Skyrizi (risankizumab) is identified as the leader in the anti-IL23 category, with Tremfya (guselkumab) also gaining traction for its cost-effectiveness. Johnson & Johnson's oral drug JNJ 77242113 shows significant potential to compete with existing treatments like Otezla (apremilast) and Sotyktu (deucravacitinib). Gain valuable insights into the current and future treatment paradigms for psoriasis, informed by expert opinions and detailed analysis.

Key brands covered in this report:

  • Humira
  • Enbrel
  • Remicade
  • Cimzia
  • Cosentyx
  • Taltz
  • Siliq/Kyntheum
  • Stelara
  • Tremfya
  • Ilumya/Ilumetri
  • Skyrizi
  • Otezla
  • Bimzelx
  • Sotyktu
  • piclidenoson
  • zasocitinib
  • JNJ 77242113

Key questions answered:

  • How are current therapies for psoriasis used and perceived in terms of efficacy, tolerability, and ease of administration? How do they compare with pipeline options?
  • Which drug class (anti-TNFs, anti-IL-12/23s, anti-IL-23s, anti-IL-17s and oral therapies) has the greatest potential to impact prescribing trends?
  • How will the launch of biosimilars and the use of current, as well as newly approved/pipeline drugs, impact the psoriasis treatment paradigm in terms of patient segment, line of therapy, and preference?
  • Are there any promising pipeline products and if so, how will they impact the current players in the market?
  • Which clinical trials have the potential to impact prescribing trends, and how will the results affect the future treatment of psoriasis?
  • How will the treatment landscape for psoriasis evolve in the future for each patient segment and line of therapy?
  • What are KOLs' demands and expectations from the psoriasis market?

Table of Contents

Executive Summary

Research Objectives

Anti-TNF drugs

  • Humira (adalimumab; AbbVie), Remicade (infliximab; Merck & Co./Johnson & Johnson Innovative Medicine), Enbrel (etanercept; Amgen), Cimzia (certolizumab; UCB)
    • Key insights summary

Anti-IL17 drugs

  • Cosentyx (secukinumab; Novartis)
    • Key insights summary
  • Taltz (ixekizumab; Lilly)
    • Key insights summary
  • Siliq (US)/Kyntheum (EU)brodalumab; Ortho Dermatologics/LEO Pharma)
    • Key insights summary
  • Bimzelx (bimekizumab; UCB)
    • Key insights summary

Anti-IL12/23 drugs

  • Stelara (ustekinumab; Johnson & Johnson Innovative Medicine)
    • Key insights summary

Anti-IL23 drugs

  • Tremfya (guselkumab; Johnson & Johnson Innovative Medicine)
    • Key insights summary
  • Ilumya/Ilumetri (tildrakizumab; Sun Pharma/Almirall)
    • Key insights summary
  • Skyrizi (risankizumab; AbbVie)
    • Key insights summary

PDE IV antagonists

  • Otezla (apremilast; Amgen)
    • Key insights summary

Tyrosine Kinase 2 inhibitor

  • Sotyktu (deucravacitinib; Bristol Myers Squibb)
    • Key insights summary

Pipeline drugs

  • Piclidenoson (Can-Fite BioPharma)
    • Key insights summary
  • Zasocitinib (TAK 279; Takeda)
    • Key insights summary
  • JNJ 77242113 (Johnson & Johnson Innovative Medicine)
    • Key insights summary

Future outlook and treatment dynamics for management of psoriasis

  • Key insights summary
    • Risankizumab, guselkumab and bimekizumab will pose strong competition to other drugs within the psoriasis treatment paradigm: biosimilars will enable early intervention with biologics

Appendix

KOL Bulletins